Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

51.50 

2.26 4.6%

as of Oct 29 '20

52 Week Range:

19.50 50.38


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, interventional fluid management, pressure monitoring, and cardiac rhythm management, as well as thermodilution and pulmonary artery catheters and electrophysiology to treat various heart conditions. It also offers cardiovascular and critical care products to treat patients with life-threatening diseases, and protect healthcare providers from exposure to bloodborne pathogens. In addition, it provides interventional oncology and spine products to treat vertebral compression fractures, metastatic spinal tumors, liver cancer, uterine fibroids, benign prostatic hyperplasia, vertebral compression fractures, and arteriovenous malformations and hemostatic embolization, as well as breast cancer localization and guidance products for the treatment of breast cancer. Further, it offers non-vascular stents to treat pulmonary and gastrointestinal diseases; dilation balloons to endoscopically dilate strictures; and kits and accessories for endoscopy and bronchoscopy procedures. Additionally, it provides coated tubes and wires; microelectromechanical system sensor components; ConvertX nephroureteral stent system; and Fibrovein, a detergent-based sclerosant. The company sells its products to hospitals and clinic-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was founded in 1987 and is headquartered in South Jordan, Utah.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 6.21
6.64
8.35
8.98
9.23
9.73
10.36
10.88
13.27
16.82
17.19
growth rate 6.9% 25.8% 7.5% 2.8% 5.4% 6.5% 5.0% 22.0% 26.8% 2.2%
Earnings BIT 33.09
16.79
32.88
27.62
19.84
40.70
38.62
37.00
64.92
73.32
54.48
growth rate -49.3% 95.8% -16.0% -28.2% 105.1% -5.1% -4.2% 75.5% 13.0% -25.7%
Avg.PE 24.45
29.24
23.09
30.03
40.82
36.13
36.25
67.89
78.79
72.65
77.88
growth rate 19.6% -21.0% 30.1% 35.9% -11.5% 0.3% 87.3% 16.1% -7.8% 7.2%
ROA 8.95
3.89
5.64
3.42
2.31
3.11
3.12
2.34
2.68
3.08
0.32
growth rate -56.5% 45.0% -39.4% -32.5% 34.6% 0.3% -25.0% 14.5% 14.9% -89.6%
ROE 10.91
5.48
7.78
5.34
4.21
5.46
5.28
4.17
4.69
5.22
0.58
growth rate -49.8% 42.0% -31.4% -21.2% 29.7% -3.3% -21.0% 12.5% 11.3% -88.9%
ROIC 10.49
4.79
6.63
3.92
3.63
4.45
4.25
3.61
3.73
4.36
1.05
growth rate -54.3% 38.4% -40.9% -7.4% 22.6% -4.5% -15.1% 3.3% 16.9% -75.9%
Cur. Ratio 2.75
2.80
3.05
2.21
2.53
2.55
2.32
2.76
2.73
2.45
2.50
growth rate 1.8% 8.9% -27.5% 14.5% 0.8% -9.0% 19.0% -1.1% -10.3% 2.0%
Quick Ratio 1.17
1.11
1.26
0.92
1.09
1.17
0.94
1.20
1.28
1.24
1.17
growth rate -5.1% 13.5% -27.0% 18.5% 7.3% -19.7% 27.7% 6.7% -3.1% -5.7%
Leverage 1.24
1.57
1.25
1.85
1.80
1.72
1.67
1.89
1.64
1.74
1.85
growth rate 26.6% -20.4% 48.0% -2.7% -4.4% -2.9% 13.2% -13.2% 6.1% 6.3%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 31.00
37.40
48.96
62.30
69.73
80.55
78.10
86.43
115.74
149.38
168.53
growth rate 20.7% 30.9% 27.3% 11.9% 15.5% -3.1% 10.7% 33.9% 29.1% 12.8%
Acct.Payable 43.80
63.00
55.59
29.81
37.98
30.62
34.93
54.02
54.62
growth rate 43.9% -11.8% -46.4% 27.4% -19.4% 14.1% 54.7% 1.1%
Cur.Assets 90.60
112.30
133.65
162.00
165.92
192.34
204.00
243.42
316.12
429.83
454.54
growth rate 24.0% 19.0% 21.2% 2.4% 15.9% 6.1% 19.3% 29.9% 36.0% 5.8%
Total Assets 271.50
369.50
447.02
705.31
728.28
747.17
778.73
942.80
1,111.81
1,620.01
1,757.32
growth rate 36.1% 21.0% 57.8% 3.3% 2.6% 4.2% 21.1% 17.9% 45.7% 8.5%
Cash 6.10
3.70
10.13
9.72
7.46
7.36
4.18
19.17
32.34
67.36
44.32
growth rate -39.3% 173.7% -4.0% -23.3% -1.4% -43.2% 359.0% 68.7% 108.3% -34.2%
Inventory 47.20
60.60
69.91
84.60
82.38
91.77
106.00
120.70
155.29
197.54
225.70
growth rate 28.4% 15.4% 21.0% -2.6% 11.4% 15.5% 13.9% 28.7% 27.2% 14.3%
Cur.Liabilities 32.90
40.20
43.80
73.00
65.59
75.43
87.91
88.33
115.62
175.34
181.66
growth rate 22.2% 8.9% 66.7% -10.2% 15.0% 16.6% 0.5% 30.9% 51.7% 3.6%
Liabilities 52.70
133.90
89.93
323.73
322.58
311.91
312.63
444.61
435.48
687.24
807.38
growth rate 154.1% -32.8% 260.0% -0.4% -3.3% 0.2% 42.2% -2.1% 57.8% 17.5%
LT Debt 0.30
82.90
30.74
227.57
238.85
214.49
197.59
314.37
259.01
373.15
431.98
growth rate 27,533.3% -62.9% 640.4% 5.0% -10.2% -7.9% 59.1% -17.6% 44.1% 15.8%
Equity 218.80
235.60
357.09
381.58
405.71
435.26
466.10
498.19
676.33
932.78
949.94
growth rate 7.7% 51.6% 6.9% 6.3% 7.3% 7.1% 6.9% 35.8% 37.9% 1.8%
Common Shares 29.00
36.00
40.00
43.00
43.00
43.00
45.00
45.00
50.00
54.00
56.00
growth rate 24.1% 11.1% 7.5% 0.0% 0.0% 4.7% 0.0% 11.1% 8.0% 3.7%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 18.50
23.60
59.20
64.64
59.51
34.18
50.96
32.84
38.62
63.32
78.17
growth rate 27.6% 150.8% 9.2% -8.0% -42.6% 49.1% -35.6% 17.6% 64.0% 23.5%
Cash Dividends 0.00 0.00 0.00 0.00
growth rate
Cash From OA 30.10
34.80
34.02
46.94
51.37
53.33
69.46
53.60
62.73
86.53
77.81
growth rate 15.6% -2.3% 38.0% 9.5% 3.8% 30.3% -22.8% 17.0% 38.0% -10.1%
FCF per Share 0.29
0.35
-0.14
-0.45
-0.39
0.27
0.62
0.19
0.46
0.44
-0.06
growth rate 20.7% -100.0% 0.0% 0.0% 100.0% 129.6% -69.4% 142.1% -4.4% -100.0%
Sale Purchase of Stock 95.33
3.76
3.73
8.15
6.67
5.27
143.81
growth rate -96.1% -0.7% 118.5% -18.1% -21.0% 2,628.3%
FCF 10.00
10.00
-27.00
-19.00
-10.00
17.00
17.00
19.00
22.00
20.00
-4.00
growth rate 0.0% -100.0% 0.0% 0.0% 100.0% 0.0% 11.8% 15.8% -9.1% -100.0%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 257.50
296.80
359.45
394.29
449.05
509.69
542.15
603.84
727.85
882.75
994.85
growth rate 15.3% 21.1% 9.7% 13.9% 13.5% 6.4% 11.4% 20.5% 21.3% 12.7%
Op.Income 32.80
17.20
23.04
19.71
16.57
40.70
38.62
37.00
64.92
73.32
54.48
growth rate -47.6% 34.0% -14.5% -15.9% 145.6% -5.1% -4.2% 75.5% 13.0% -25.7%
IBT 33.10
16.80
32.88
27.62
19.84
31.57
31.20
25.39
35.88
49.52
2.19
growth rate -49.2% 95.7% -16.0% -28.2% 59.1% -1.2% -18.6% 41.3% 38.0% -95.6%
Net Income 22.50
12.50
23.04
19.71
16.57
22.97
23.80
20.12
27.52
42.02
5.45
growth rate -44.4% 84.4% -14.5% -15.9% 38.7% 3.6% -15.5% 36.8% 52.7% -87.0%
EPS 0.79
0.35
0.58
0.46
0.39
0.53
0.53
0.45
0.55
0.78
0.10
growth rate -55.7% 65.7% -20.7% -15.2% 35.9% 0.0% -15.1% 22.2% 41.8% -87.2%
Gross Profit 108.80
128.50
165.47
181.99
194.37
225.22
235.78
265.03
326.25
394.77
432.37
growth rate 18.1% 28.8% 10.0% 6.8% 15.9% 4.7% 12.4% 23.1% 21.0% 9.5%
R&D 11.20
15.30
21.94
27.80
33.89
36.63
40.81
45.23
51.40
59.53
65.62
growth rate 36.6% 43.4% 26.7% 21.9% 8.1% 11.4% 10.8% 13.7% 15.8% 10.2%

Quarterly Statements

Item Name Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Earnings BIT 15.66
0.21
28.29
10.12
3.45
growth rate -98.6% 13,179.3% -64.2% -65.9%
Balance Sheet Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Acct.Receivable 172.22
165.49
168.53
164.88
157.47
growth rate -3.9% 1.8% -2.2% -4.5%
Acct.Payable 52.60
52.39
54.62
56.01
44.44
growth rate -0.4% 4.3% 2.5% -20.7%
Cur.Assets 426.95
441.30
454.54
462.51
445.95
growth rate 3.4% 3.0% 1.8% -3.6%
Total Assets 1,736.27
1,761.70
1,757.32
1,749.27
1,715.87
growth rate 1.5% -0.3% -0.5% -1.9%
Cash 35.18
37.32
44.32
50.08
49.70
growth rate 6.1% 18.8% 13.0% -0.8%
Inventory 202.99
216.77
225.70
227.78
221.42
growth rate 6.8% 4.1% 0.9% -2.8%
Cur.Liabilities 176.55
153.21
181.66
165.29
174.22
growth rate -13.2% 18.6% -9.0% 5.4%
Liabilities 785.60
812.46
807.38
809.47
787.02
growth rate 3.4% -0.6% 0.3% -2.8%
LT Debt 385.22
432.46
431.98
442.95
408.23
growth rate 12.3% -0.1% 2.5% -7.8%
Equity 950.68
949.24
949.94
939.80
928.85
growth rate -0.2% 0.1% -1.1% -1.2%
Common Shares 579.25
584.16
587.02
590.07
595.73
growth rate 0.9% 0.5% 0.5% 1.0%
Cash Flow Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Capital Expenditures 17.70
22.15
20.07
13.95
11.85
growth rate 25.1% -9.4% -30.5% -15.0%
Cash Dividends
growth rate
Cash From OA 22.19
15.21
26.91
28.86
44.35
growth rate -31.4% 76.9% 7.3% 53.7%
Sale Purchase of Stock
growth rate
FCF 4.48
-6.93
6.84
14.91
32.50
growth rate -100.0% 100.0% 118.0% 117.9%
Income Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Sales 255.53
243.05
257.92
243.53
218.37
growth rate -4.9% 6.1% -5.6% -10.3%
Op.Income 15.66
0.21
28.29
10.12
3.45
growth rate -98.6% 13,179.3% -64.2% -65.9%
IBT 9.00
-5.69
-7.96
-1.99
-22.30
growth rate -100.0% 0.0% 0.0% 0.0%
Net Income 6.86
-3.40
-4.21
-3.15
-19.06
growth rate -100.0% 0.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 111.96
104.14
111.63
103.78
84.22
growth rate -7.0% 7.2% -7.0% -18.9%
R&D 16.33
16.99
16.25
14.87
14.03
growth rate 4.0% -4.3% -8.5% -5.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (21.05)

YOY Growth Grade:

D (39.86)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE 77.88 -95.37 26.95
EPS / Growth 15.1% -0.54 12.5%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 15.6%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 12.5% 14.4% 14.4%
Future PE 25.06 27.87 27.87
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.